All Articles tagged PROPEL
Genetic Disorders
September 18, 2024 EDT This analysis of EQ-5D health-related quality-of-life utility data from the PROPEL clinical trial compared cipaglucosidase alfa plus miglustat vs alglucosidase alfa plus placebo in late-onset Pompe disease.